A new trading day began on Tuesday, with Apellis Pharmaceuticals Inc (NASDAQ: APLS) stock price down -2.79% from the previous day of trading, before settling in for the closing price of $25.11. APLS’s price has ranged from $23.77 to $59.91 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 92.54% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged 37.94%. With a float of $104.48 million, this company’s outstanding shares have now reached $124.50 million.
In an organization with 710 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 84.82%, operating margin of -21.11%, and the pretax margin is -25.18%.
Apellis Pharmaceuticals Inc (APLS) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Apellis Pharmaceuticals Inc is 16.76%, while institutional ownership is 99.44%. The most recent insider transaction that took place on Mar 17 ’25, was worth 4,543. In this transaction VP/Chief Accounting Officer of this company sold 183 shares at a rate of $24.82, taking the stock ownership to the 47,955 shares. Before that another transaction happened on Mar 17 ’25, when Company’s Officer proposed sale 183 for $24.82, making the entire transaction worth $4,543.
Apellis Pharmaceuticals Inc (APLS) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.26 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 37.94% per share during the next fiscal year.
Apellis Pharmaceuticals Inc (NASDAQ: APLS) Trading Performance Indicators
Here are Apellis Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 3.81. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.92.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.60, a number that is poised to hit -0.34 in the next quarter and is forecasted to reach 0.17 in one year’s time.
Technical Analysis of Apellis Pharmaceuticals Inc (APLS)
Let’s dig in a bit further. During the last 5-days, its volume was 1.37 million. That was inferior than the volume of 1.71 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 33.92%. Additionally, its Average True Range was 1.14.
During the past 100 days, Apellis Pharmaceuticals Inc’s (APLS) raw stochastic average was set at 5.36%, which indicates a significant decrease from 16.98% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 41.02% in the past 14 days, which was lower than the 54.57% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $28.18, while its 200-day Moving Average is $32.94. However, in the short run, Apellis Pharmaceuticals Inc’s stock first resistance to watch stands at $24.92. Second resistance stands at $25.43. The third major resistance level sits at $25.83. If the price goes on to break the first support level at $24.01, it is likely to go to the next support level at $23.61. Assuming the price breaks the second support level, the third support level stands at $23.10.
Apellis Pharmaceuticals Inc (NASDAQ: APLS) Key Stats
With a market capitalization of 3.06 billion, the company has a total of 125,516K Shares Outstanding. Currently, annual sales are 781,370 K while annual income is -197,880 K. The company’s previous quarter sales were 212,530 K while its latest quarter income was -36,350 K.
